Literature DB >> 32552949

[Neutrophil-Lymphocyte Ratio as a Prognostic Predictor in Patients with Newly Diagnosed Angioimmunoblastic T Cell Lymphoma].

Yu-Qiong Yang1, He-Sheng He1, Yan Dai1, Xiao-Ke Jin1, Jia-Jia Li2, Chen Huang1, Jun Huang1, Jing Qi1, Jia-Wei Yan1, Dong-Ping Huang3.   

Abstract

OBJECTIVE: To investigate the prognostic evaluation value of neutrophil-lymphocyte ratio (NLR) in patients with newly diagnosed angioimmunoblastic T cell lymphoma (AITL).
METHODS: Clinical data of 39 patients with newly diagnosed AITL in our hospital from March 2010 to August 2018 were colleated and retrospective analyzied, and the relationship between NLR before treatment and the prognosis of AITL patients was analyzed.
RESULTS: Among 39 AITL patients, the median value of NCR was 5.43. Based on the cut-off value (5.43), all the patients were divided into 2 groups: high NLR group (5.43, n=20) and a low NLR group (<5.43, n=19). The total effective rate of treatment was lower in the high NLR group as compered with low NLR group (P=0.041). Univariate analysis showed that, age >60 years old, extranodal involvement>1 as well as high NLR were the independent risk factors that affected overall survival (OS) in newly diagnosed AITL patients. Multivariate Cox analysis showed that extranodal involvement>1 and high NLR were the independent risk factors that affected OS in newly diagnosed AITL patients.
CONCLUSION: The NLR may be an independent prognostic factor in patients with newly diagnosed AITL. High NLR associated with poor prognosis.

Entities:  

Mesh:

Year:  2020        PMID: 32552949     DOI: 10.19746/j.cnki.issn.1009-2137.2020.03.024

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  1 in total

Review 1.  Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis.

Authors:  Jia Liu; Shengnan Zhang; Ruihua Mi; Lin Chen; Qingsong Yin
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.